Comparison of IVF-ET outcomes with GnRH antagonist started either on stimulation day 1 and 6 vs. conventional GnRH agonist long protocol in patients with polycystic ovary syndrome

A multicentre, prospective randomized study to assess the effect when GnRH antagonist is started either on stimulation day 1 and day 6 vs. conventional GnRH agonist long protocol in patients with polycystic ovary syndrome undergoing IVF/ET

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CRIS

Registry ID

KCT0000157

Enrollment

267

Registered

2011-07-28

Start date

2011-06-27

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Drug: GnRH antagonist (Cetrotide) In the first arm, cetrotide will be administrated from the first day during stimulation. In the second arm, cetrotide will be administrated from the sixth day

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: PCOS patients (diagnosed as 2003 ASRM/ESHRE consensus meeting guideline) age 20-40 years patients who have normal uterus

Exclusion criteria

Exclusion criteria: patients who have abnormal thyroid function patients who have abnormal prolactin test patients who have diabetes, or Cushing's syndrome, or congenital adrenal hyperplasia, or androgen-producing tumor. Patients who reject informed consent patients who have experience of adverse events for GnRH agonist, antagonist, recombinant FSH.

Design outcomes

Primary

Measure	Time frame
number of oocyte retrieved	—

Secondary

Measure	Time frame
pregnancy rate	—

Countries

Korea, Republic of

Contacts

Public ContactKyung Eui Park

Seoul National University Hospital

Outcome results